Bing Xia, MD, discusses the latest immunotherapy developments in nonsquamous non–small cell lung cancer, as well as sequencing strategies for patients with ALK-positive disease.
Original Article: Navigating Frontline Therapy and Treatment Beyond Progression in NSCLC